Anti‑angiogenic effect of Livistona chinensis seed extract in vitro and in vivo

Cao,Zhiyun; Zheng,Liangpu; Zhao,Jinyan; Zhuang,Qunchuan; Hong,Zhenfeng; Lin,Wei

doi:10.3892/ol.2017.7075

Anti‑angiogenic effect of Livistona chinensis seed extract in vitro and in vivo

Authors:
- Zhiyun Cao
- Liangpu Zheng
- Jinyan Zhao
- Qunchuan Zhuang
- Zhenfeng Hong
- Wei Lin
View Affiliations

Affiliations: Academy of Integrative Medicine Biomedical Research Center, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China
Published online on: September 27, 2017 https://doi.org/10.3892/ol.2017.7075
Pages: 7565-7570

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to detect the impact of the ethanol extract of the Livistona chinensis seed (EELC) on angiogenesis in human umbilical vein endothelial cells (HUVECs). A chorioallantoic membrane (CAM) assay was used to detect the anti‑angiogenic activity of EELC in vivo. In vitro, the effect of EELC on the proliferation, migration and angiogenesis of HUVECs was determined by an MTT assay, a wound healing assay and a tube formation assay, respectively. The vascular endothelial growth factor (VEGF)‑A and VEGF receptor (VEGFR)‑2 protein and mRNA level were measured with ELISA and reverse transcription‑semi‑quantitative polymerase chain reaction. It was observed that EELC significantly decreased the formation of new vessels in the CAM assay. EELC inhibited the proliferation and migration of HUVECs. The extent of tube formation by HUVECs was also reduced by EELC. In addition, EELC treatment reduced the level of VEGF‑A and VEGFR‑2 mRNA and protein. The results suggest that EELC inhibits tumor angiogenesis through inhibiting the proliferation and migration of HUVECs, and by downregulating VEGF and VEGFR.

View Figures

View References

1	Chen XZ, Cao ZY, Chen TS, Zhang YQ, Liu ZZ, Su YT, Liao LM and Du J: Water extract of Hedyotis diffusa Willd suppresses proliferation of human HepG2 cells and potentiates the anticancer efficacy of low-dose 5-fluorouracil by inhibitingthe CDK2-E2F1 pathway. Oncol Rep. 28:742–748. 2012. View Article : Google Scholar : PubMed/NCBI
2	Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
3	Shih T and Lindley C: Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 28:1779–1802. 2006. View Article : Google Scholar : PubMed/NCBI
4	Gotink KJ and Verheul HM: Anti-angiogenic tyrosine kinase inhibitors: What is their mechanism of action? Angiogenesis. 13:1–14. 2010. View Article : Google Scholar : PubMed/NCBI
5	Cook KM and Figg WD: Angiogenesis inhibitors: Current strategies and future prospects. CA Cancer J Clin. 60:222–243. 2010. View Article : Google Scholar : PubMed/NCBI
6	Wang H, Li A, Dong XP and Xu XY: Screening of anti-tumor parts from the seeds of Livistona chinensis and its anti-angiogenesis effect. Zhong Yao Cai. 31:718–722. 2008.(In Chinese). PubMed/NCBI
7	Cheueng S and Tai J: In vitro studies of the dry fruit of Chinese fan palm Livistona chinensis. Oncol Rep. 5:1331–1336. 2005.
8	Sartippour MR, Liu C, Shao ZM, Go VL, Heber D and Nguyen M: Livistona extract inhibits angiogenesis and cancer growth. Oncol Rep. 6:1355–1357. 2001.
9	Huang WC, Hsu RM, Chi LM, Leu YL, Chang YS and Yu JS: Selective downregulation of EGF receptor and downstream MAPK pathway in human cancer cell lines by active components partially purified from the seeds of Livistona chinensis R. Brown. Cancer Lett. 248:137–146. 2007. View Article : Google Scholar : PubMed/NCBI
10	Lin W, Zhao J, Cao Z, Zhuang Q, Zheng L, Cai Q, Chen D, Wang L, Hong Z and Peng J: Livistona chinensis seed suppresses hepatocellular carcinoma growth through promotion of mitochondrial-dependent apoptosis. Oncol Rep. 29:1859–1866. 2013. View Article : Google Scholar : PubMed/NCBI
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
12	Folkman J and Shing Y: Angiogenesis. J Biol Chem. 267:10931–10934. 1992.PubMed/NCBI
13	Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995. View Article : Google Scholar : PubMed/NCBI
14	Folkman J: Angiogenesis. Annu Rev Med. 57:1–18. 2006. View Article : Google Scholar : PubMed/NCBI
15	Shweiki D, Itin A, Soffer D and Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:843–845. 1992. View Article : Google Scholar : PubMed/NCBI
16	Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Britman ML and Schuh AC: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 376:62–66. 1995. View Article : Google Scholar : PubMed/NCBI
17	Lin W, Zhao J, Cao Z, Zhuang Q, Zheng L, Zeng J, Hong Z and Peng J: Livistona chinensis seeds inhibit hepatocellular carcinoma angiogenesis in vivo via suppression of the Notch pathway. Oncol Rep. 31:1723–1728. 2014. View Article : Google Scholar : PubMed/NCBI
18	Siekmann AF and Lawson ND: Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries. Nature. 445:781–784. 2007. View Article : Google Scholar : PubMed/NCBI
19	Suchting S, Freitas C, le Noble F, Benedito R, Bréant C, Duarte A and Eichmann A: The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci USA. 104:pp. 3225–3230. 2007, View Article : Google Scholar : PubMed/NCBI
20	Ferrara N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications. Semin Oncol. 29 6 Suppl 16:S10–S14. 2002. View Article : Google Scholar
21	Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med. 9:669–676. 2003. View Article : Google Scholar : PubMed/NCBI
22	Zachary I and Gliki G: Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res. 49:568–581. 2001. View Article : Google Scholar : PubMed/NCBI
23	Williams CK, Li JL, Murga M, Harris AL and Tosato G: Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood. 107:931–939. 2006. View Article : Google Scholar : PubMed/NCBI
24	Wang G, Ye Y, Zhang X, Liu H and Song J: A single-arm clinical study of continuous usage of bevacizumab assecond-line chemotherapy for Chinese patients with metastatic colorectal cancer. Med Oncol. 32:1632015. View Article : Google Scholar : PubMed/NCBI
25	Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol. 26:2013–2019. 2008. View Article : Google Scholar : PubMed/NCBI